CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) ...

For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD). The drug is ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in adults ...

Aug. 26—Those at risk of a severe allergic reaction always have handy an EpiPen just in case. But soon their life might be saved by a spray in the nose rather than a needle to the thigh. Last week the ...

The FDA orders the recall of a nasal spray in the US after finding live microbes; immunocompromised patients are at greatest ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made ...

The FDA has approved an at-home nasal spray flu vaccine, and it’s now available for order. FluMist enters the bloodstream after being sprayed in your nasal passage and helps build up antibodies to ...

WASHINGTON -- Regulators at the U.S. Food and Drug Administration declined to approve a needle-free nasal spray equivalent to an EpiPen, pending further study, according to the company developing it.